Herpes simplex virus is a double-stranded DNA virus that infects skin and nerve tissue, then hides for life inside sensory neurons, where it can reactivate intermittently and cause cold sores, genital lesions, or asymptomatic shedding. Two types exist: HSV-1 spreads mainly through oral contact and causes most cold sores, while HSV-2 spreads mainly through sexual contact and causes most recurrent genital herpes. Neither has a cure. Antiviral drugs shorten and suppress outbreaks but do not clear the latent virus.
The virus is extremely common: roughly half of adults worldwide carry HSV-1, and hundreds of millions carry HSV-2. Most carriers have no symptoms, so transmission often occurs without anyone knowing an outbreak is happening.
The entry-and-latency cycle
HSV infects through small breaks in skin or mucous membrane. The virion's envelope glycoproteins attach to cell-surface heparan sulfate, and glycoprotein D then binds one of three receptors: herpesvirus entry mediator, nectin-1, or 3-O-sulfated heparan sulfate. This binding triggers fusion of the viral envelope with the cell membrane, delivering the capsid and tegument proteins into the cytoplasm.
The virus then moves along microtubules to the nucleus, where it begins transcription and replication. At the skin surface, this produces the characteristic vesicle, a fluid-filled blister sitting on a red base. From the infected skin, virions travel retrograde along sensory nerve axons to the neuronal cell body in a dorsal root ganglion or trigeminal ganglion.
Inside the neuron, HSV can enter one of two states. In the lytic state, it replicates and destroys the cell. In the latent state, it circularizes its genome and expresses almost nothing except a set of latency-associated transcripts, which help it stay silent and evade immune detection. Latency is why neither drugs nor the immune system can clear the infection: the virus is not replicating, so there is little for either to target.
Reactivation is triggered by several factors, including ultraviolet light, fever, physical trauma, psychological stress, and hormonal changes. When these signals reactivate the virus, it travels anterograde back down the axon to the skin, causing a recurrent lesion or shedding virus with no visible symptoms. The ability to shed without lesions is central to how HSV spreads so efficiently.
Latency, reactivation, and shedding frequency
Several exact numbers put this into perspective. Antivirals reduce but do not stop shedding: oral valacyclovir lowers the frequency of subclinical shedding by about 70-80 percent, according to randomized trials summarized by the CDC.
The biology is more or less stable across people, but the numbers that matter for transmission vary hugely:
HSV-1: about half of all adults worldwide carry the virus, according to WHO estimates, though seroprevalence varies widely by region. HSV-2: worldwide prevalence is roughly 12 percent among adults, again according to WHO estimates, and it is significantly higher in some regions and age groups than in others. Asymptomatic or unrecognized infection: the majority of people who test positive for HSV-2 report no history of genital lesions. Shedding: documented subclinical shedding occurs on a substantial fraction of days even in people with no visible lesions; in studies of people with genital HSV-2, shedding has been detected on roughly one in five to one in three days, varying by study design. Vertical transmission: neonatal HSV occurs in roughly 1 in 2,500 to 1 in 10,000 live births in the United States, with higher rates when a mother has a primary infection near delivery.
Shedding frequency declines slowly over time. A person with long-standing HSV-2 infection typically sheds less often and has fewer recurrences than someone in the first years after acquisition.
When the disease is not routine
Most HSV disease is annoying but self-limited. A group of cases, however, become serious and require urgent care, and they are the ones clinicians watch for.
Neonatal herpes is the most dangerous. When a newborn is exposed to the virus during delivery, usually from a primary maternal infection, it can develop disseminated disease affecting the liver, lungs, or central nervous system. Without treatment, mortality from disseminated neonatal HSV is high; prompt intravenous antiviral therapy changes the outlook substantially. Any newborn with vesicles, lethargy, poor feeding, or seizures in the first weeks of life needs emergency evaluation.
Herpes simplex encephalitis is a rare but catastrophic complication, typically caused by HSV-1. It presents as fever, headache, confusion, or seizures, and it can progress rapidly. Untreated, it is fatal in roughly 70 percent of cases; even with treatment, many survivors have lasting neurologic deficits.
In immunocompromised patients, including those with advanced HIV, transplant recipients, and people receiving chemotherapy, HSV can cause large chronic ulcers, esophagitis, pneumonitis, or hepatitis. Immune compromise turns a nuisance infection into a serious one.
Ocular herpes, usually HSV-1, causes keratitis and is the leading infectious cause of corneal blindness in high-income countries. Repeated bouts of inflammation and treatment can scar the cornea permanently.
This is where a key professional caveat applies: a negative serology does not exclude infection in the newborn setting or in the very recently exposed, because antibody formation takes days to weeks. Clinicians therefore rely on PCR and clinical findings, not just blood tests.
| Situation | Typical presentation | Diagnostic priority | Main risk |
|---|---|---|---|
| Oral HSV-1 | Cold sore on lips | Clinical diagnosis | Corneal infection |
| Genital HSV-2 | Painful genital blisters or ulcers | PCR from lesion swab | Neonatal transmission |
| Genital HSV-1 | First-episode genital ulcer | PCR from lesion swab | Less frequent recurrence |
| Neonatal HSV | Vesicles, lethargy, fever | PCR of blood and cerebrospinal fluid | Disseminated disease |
| Herpes encephalitis | Fever, confusion, seizures | CSF PCR and MRI | Neurologic damage |
| Ocular HSV | Eye pain, redness, tearing | Slit-lamp exam | Corneal scarring |
| Immunocompromised HSV | Chronic ulcers, esophagitis | PCR and endoscopy | Disseminated disease |
The misconceptions that spread
The biggest misconception is that herpes only spreads when there are visible sores. It does not. Asymptomatic shedding is common enough to account for a large share of transmissions, which is why public health guidance treats condoms and antiviral suppression as imperfect but real risk reduction. Condoms reduce but do not eliminate transmission, because lesions and shedding can occur on skin not covered by a condom.
A second misconception is that HSV-1 only causes cold sores and HSV-2 only causes genital herpes. The two viruses can each cause disease at either site. Oral sex has become an important route of genital HSV-1 acquisition, and in some high-income countries HSV-1 is now the leading cause of first-episode genital herpes among young women. The site matters less than the virus type for recurrence patterns.
A third misconception is that blood tests are routine and definitive. Type-specific serology can be useful, but sensitivity varies, and false positives occur at low prevalence. The CDC advises against routine screening of asymptomatic adults because the psychosocial and clinical consequences of a positive result are substantial and the test does not change transmission management in most cases.
A counterintuitive detail is that HSV does not cause most of the diseases it is blamed for. It is not a cause of cervical cancer, oral cancer, or infertility. HSV-1 and HSV-2 are associated with increased HIV acquisition risk, but that is because genital ulcers create entry points, not because HSV causes HIV. Meanwhile, HSV-2 seroprevalence has declined in the United States in recent decades, mostly for reasons that remain only partly explained, likely including changes in sexual behavior and condom use.
What to do with an HSV infection
Concrete steps depend on whether someone has symptoms, a partner with HSV, or a positive test without symptoms. The core actions:
Confirm the diagnosis with a lesion PCR swab, not just a visual exam, when the diagnosis will guide treatment or disclosure; PCR is far more sensitive than viral culture and is the preferred test in current guidance. For recurrent lesions, start antiviral therapy at the first sign of tingling or burning, not after the blister appears. A standard approach is a short course of oral therapy. Patients with frequent recurrences typically benefit from daily suppressive therapy. Ask a clinician about daily suppressive therapy if recurrences are frequent (many clinicians consider roughly six or more per year). Suppressive therapy can cut both viral shedding and transmission to a susceptible partner. For a pregnant person with known genital HSV, tell the obstetric team early, because management of the last trimester differs; a cesarean delivery may be recommended for active lesions or prodromal symptoms at the time of labor. For close contacts who are immunocompromised or pregnant, avoid contact with active lesions and use barrier protection. Red flag warnings that need emergency care: a newborn with blisters, lethargy, or poor feeding; a person with confusion, severe headache, or seizures; an immunocompromised person with rapidly spreading ulcers.
A common practical question is whether to test an asymptomatic partner. The short answer is that routine testing is not recommended by the CDC for adults without symptoms, but the decision changes if a partner has a known infection, if pregnancy is planned, or if symptoms are ambiguous. In those settings, type-specific serology can be reasonable after discussing the limits of the test.
Testing, treatment, and what current evidence cannot settle
Diagnostically, PCR of a swab from a fresh lesion is the preferred method. Culture is less sensitive and takes longer. Blood tests detect antibodies and can tell HSV-1 from HSV-2, but they take weeks to become positive after exposure and can cross-react at low cutoff values. A positive result should be interpreted in the context of symptoms and history.
Treatment relies on three nucleoside analogues: acyclovir, valacyclovir, and famciclovir. They work because HSV encodes a thymidine kinase, and these drugs need viral thymidine kinase to become activated. The activated drug inhibits viral DNA polymerase and stops replication. Because latent virus is not replicating, the drugs cannot reach or eliminate it; they only shorten and prevent active episodes. This is also why treatment does not cure the infection and why a person remains capable of transmitting HSV after the medication course ends.
There is also a professional caution worth naming explicitly: the evidence base for many long-term management decisions is weaker than the confidence of popular advice suggests. Suppressive therapy reduces, but does not eliminate, transmission. Condoms reduce, but do not eliminate, risk. Behavioral counseling has modest effects. A person can do everything recommended and still transmit HSV, because shedding without lesions is a normal part of the biology.
No licensed prophylactic vaccine exists. Several candidates have been tested in clinical trials, but none has reached routine use. Researchers continue to pursue vaccines and novel antivirals aimed at latency, but as of current evidence none have been approved for prevention.
Randomized trial evidence for suppressive therapy comes primarily from genital HSV-2 cohorts that may not, in principle, extend perfectly to HSV-1 genital infections or to populations with different immune status.
What the evidence cannot settle is the exact shedding rate for an individual patient, the precise transmission risk for a given couple, and the true seroprevalence in every population. Public health figures are population averages, not personal predictions. A clinician can give a range but not a guarantee. That limitation is not a reason for fatalism; it is a reason to treat the virus accurately, disclose honestly, and use the tools that demonstrably reduce risk without promising more than they deliver.